Retatrutide
Retatrutide is a GIP, GLP-1 and glucagon receptor agonist.
- Content per vial
- 20 mg
- Product form
- Lyophilized powder
- Order unit
- 10 vials / box
- Catalogue price
- AUD 1,800
One molecule, three receptors.
Three biological targets linked to appetite, body weight and metabolism.
Retatrutide activates GIP, GLP-1 and glucagon receptors in a single molecule. Its activity at these three receptors underpins its development in obesity and metabolic research.
- GIP
- Glucose-dependent insulinotropic polypeptide
- GLP-1
- Glucagon-like peptide-1
- Glucagon
- Glucagon
Clinical development status.
Retatrutide is investigational and not yet approved by regulators. Clinical trials evaluate benefits, risks and tolerability for specific formulations and protocols. That evidence does not automatically apply to every product sold under the same name.
Retatrutide clinical statusProduct form and storage matter.
Store and handle the product according to its label and batch documentation.
Product form
Retatrutide is supplied as lyophilized powder. Check the storage conditions and shelf life for the specific product form, whether powder or solution.
Batch information
Confirm product identity, content, storage instructions and the testing documentation available for the batch.
Everyday habits still matter.
Consider eating habits, hydration and physical activity when discussing weight management. Review individual needs and health conditions with a qualified healthcare professional.
- Eating habits
- Hydration
- Physical activity
Vial content is not a dose.
Does 20 mg describe a recommended dose?
20 mg is the catalogue content per vial. It is not an individual dose recommendation or an instruction for use.
What should I confirm before ordering?
Check content, batch documentation, storage conditions, availability and shipping. Discuss medical questions and individual needs with an appropriately qualified healthcare professional.
Confirm your Retatrutide details.
Check availability, specifications, shipping costs and payment details with our team before ordering.
Back to the catalogueScientific references
Retatrutide development information and published clinical research.
Scientific context checked on 27 October 2026.